MAPT and progressive supranuclear palsy: In clinical cohort 2, the progressive supranuclear palsy and acute neurological disorders groups had normal levels of CSF Aβ1-42. CSF t-tau and p-tau levels were significantly higher in CJD and acute neurological disorders versus progressive supranuclear palsy (P < 0.0001).